Spyre Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Spyre Therapeutics, Inc. (SYRE), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are SYRE insiders buying or selling?
In the last 12 months, Spyre Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 30 sales ($442.5M) — net selling of $442.5M. Since May 2018, Trabud has recorded 50 Form 4 filings for SYRE: 12 buys ($2.8M) and 38 sells ($445.1M).
Source: SEC EDGAR Form 4
What stands out
- No Spyre Therapeutics, Inc. insider made an open-market purchase in the last 12 months; the 30 reported open-market sales totaled $442.5M.
Key Statistics (May 2018 – Oct 3, 2026)
Total Form 4 filings
50
SEC EDGAR
Insider filers
14
Insider buys (12)
$2.8M
Insider sells (38)
$445.1M
Insider sentiment
Net sellingNet insider flow of $442.3M in net selling since May 2018, and $442.5M in net selling over the last 12 months.
Recent SYRE insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 3, 2026 | Heidy King-Jones | Chief Legal Officer and Corporate Secretary | Sale | 28.9K | $91.03 | $2.6M | SEC ↗ |
| Oct 3, 2026 | Cameron Turtle | Chief Executive Officer | Sale | 15.0K | $92.01 | $1.4M | SEC ↗ |
| Oct 3, 2026 | Scott L Burrows | Chief Financial Officer | Sale | 25.0K | $90.47 | $2.3M | SEC ↗ |
| Sep 4, 2026 | Heidy King-Jones | Officer | Sale | 28.4K | $87.35 | $2.5M | SEC ↗ |
| Sep 4, 2026 | Scott L Burrows | Chief Financial Officer | Sale | 25.7K | $88.75 | $2.3M | SEC ↗ |
| Sep 4, 2026 | Cameron Turtle | Chief Executive Officer | Sale | 15.0K | $87.29 | $1.3M | SEC ↗ |
| Aug 11, 2026 | Jeffrey W. Albers | Director | Sale | 23.0K | $104.53 | $2.4M | SEC ↗ |
| Aug 6, 2026 | Scott L Burrows | Chief Financial Officer | Sale | 7.5K | $95.57 | $716.8K | SEC ↗ |
| Aug 6, 2026 | Cameron Turtle | Chief Executive Officer | Sale | 15.0K | $95.51 | $1.4M | SEC ↗ |
| Jul 3, 2026 | Scott L Burrows | Chief Financial Officer | Sale | 7.5K | $87.74 | $658.0K | SEC ↗ |
| Jul 3, 2026 | Sheldon Sloan | Chief Medical Officer | Sale | 8.3K | $87.70 | $730.9K | SEC ↗ |
| Jul 3, 2026 | Cameron Turtle | Chief Executive Officer | Sale | 15.0K | $87.69 | $1.3M | SEC ↗ |
| Jun 27, 2026 | Scott L Burrows | Chief Financial Officer | Sale | 15.0K | $87.13 | $1.3M | SEC ↗ |
| Jun 24, 2026 | Tomas Kiselak | Director | Sale | 4.7M | $85.31 | $399.7M | SEC ↗ |
| Jun 24, 2026 | Michael Thomas Henderson | Director | Sale | 20.0K | $100.00 | $2.0M | SEC ↗ |
| Jun 4, 2026 | Sheldon Sloan | Chief Medical Officer | Sale | 8.3K | $75.00 | $625.0K | SEC ↗ |
| Jun 4, 2026 | Cameron Turtle | Chief Executive Officer | Sale | 15.0K | $70.43 | $1.1M | SEC ↗ |
| Jun 4, 2026 | Scott L Burrows | Chief Financial Officer | Sale | 7.5K | $71.06 | $532.9K | SEC ↗ |
| May 9, 2026 | Michael Thomas Henderson | Director | Sale | 80.0K | $74.40 | $6.0M | SEC ↗ |
| May 2, 2026 | Scott L Burrows | Chief Financial Officer | Sale | 12.5K | $71.37 | $892.1K | SEC ↗ |
| May 2, 2026 | Sheldon Sloan | Chief Medical Officer | Sale | 78.3K | $71.50 | $5.6M | SEC ↗ |
| May 2, 2026 | Cameron Turtle | Chief Executive Officer | Sale | 15.0K | $71.37 | $1.1M | SEC ↗ |
| Apr 4, 2026 | Cameron Turtle | Chief Executive Officer | Sale | 15.0K | $49.33 | $739.9K | SEC ↗ |
| Apr 4, 2026 | Sheldon Sloan | Chief Medical Officer | Sale | 8.0K | $50.00 | $397.9K | SEC ↗ |
| Apr 4, 2026 | Scott L Burrows | Chief Financial Officer | Sale | 7.5K | $49.34 | $370.1K | SEC ↗ |
Showing the 25 most recent of 50 Form 4 filings for Spyre Therapeutics, Inc..
Most active SYRE insiders
- Cameron Turtle11 filings
- Scott L Burrows11 filings
- Anthony G. Quinn7 filings
- Sheldon Sloan4 filings
- Jeffrey W. Albers3 filings
Ask anything about SYRE insider activity
Use Trabud's AI agent to query Spyre Therapeutics, Inc.'s Form 4 history in plain English — "Show me SYRE CEO purchases this year" or compare it against any other ticker.
Open the AI agentSYRE insider trading FAQ
Are Spyre Therapeutics, Inc. insiders buying or selling?
In the last 12 months, Spyre Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 30 sales ($442.5M) — net selling of $442.5M. Since May 2018, Trabud has recorded 50 Form 4 filings for SYRE: 12 buys ($2.8M) and 38 sells ($445.1M). Over the full record that is net selling of $442.3M.
How many insiders trade SYRE stock?
14 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Spyre Therapeutics, Inc.. The most recent filing was accepted on Oct 3, 2026.
Where does Trabud get SYRE insider trading data?
All SYRE insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.